Tevogen Inc. (TVGN) · Nov 2, 2026 · Share issuance

Tevogen financing amended as CEO gets 50M performance shares

$7.4M debt repaid — 1,023,733 shares issued for $7.4M principal plus $177,880 interest

Tevogen’s financing amendment eliminates existing liabilities and extends borrowing access, but a 50M-share CEO award sharply concentrates voting control.

Tevogen is a pre-commercial biotechnology company pursuing personalized T-cell therapies while broadening into healthcare services and acquisition-led growth. Its earlier September award already tied executive compensation to a $1 billion revenue target, so performance-based equity and aggressive growth ambitions were known; this filing materially changes the scale and financing mechanics.

The financing removes an immediate liability without using cash, but pays for it in equity. Tevogen issued 1,000,000 principal shares and 23,733 interest shares to eliminate $7.4 million of principal and $177,880 of accrued interest. The amendment also leaves as much as $28.6 million of borrowing capacity available through May 31, 2029, extending the company’s funding runway, but that capital comes with future share issuance risk and is not cash already in hand.

The CEO award is the filing’s most consequential new signal. Ryan Saadi receives 50 million restricted shares that vest only if Tevogen reaches $1 billion in aggregate revenue by December 31, 2031. That performance hurdle aligns economic value with a very ambitious outcome, but the shares carry voting rights before vesting; after the grant and debt repayment, Saadi held approximately 90.9% of voting power. 〔0〕 This makes the award more than ordinary long-term compensation: it further entrenches control while increasing the potential dilution burden if the target is achieved.

The financing terms are less immediately punitive than the old structure, but still make equity the company’s repayment currency. The amendment fixes share repayments at $7.40 per share, adds resale restrictions, caps lender ownership at 9.99%, and preserves a 19.99% issuance cap absent stockholder approval. Those protections reduce some near-term financing uncertainty, yet the company remains dependent on a facility that can ultimately create millions of additional shares rather than simply funding operations with conventional debt.

Bottom line: Tevogen buys balance-sheet relief and longer access to capital, but the price is more equity dependence and sharply greater founder control. The event is genuinely material, though its benefits are offset by dilution and governance concentration rather than cleanly advancing the business story.

What to watch next

Registration statement for issued shares within 15 calendar days

Original filing on SEC EDGAR